Vivos Therapeutics to Participate in Online Fireside Chat with Water Tower Research on December 16, 2025, at 11 am EST
Rhea-AI Summary
Vivos Therapeutics (NASDAQ: VVOS) announced that CEO Kirk Huntsman and CFO Brad Amman will join a Water Tower Research fireside chat on December 16, 2025 at 11:00 am ET.
Management will discuss the company’s strategic business model pivot, operational execution, the market opportunity and competitive environment for sleep-related breathing disorder treatments, and Vivos’ growth and financial strategies. The event is listen-only and requires registration. A replay will be available for 30 days in the Investor Relations section at vivos.com.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus 1 Up
Sector peers were mixed: ADGM -15.17%, MYO -7.41%, COCH -6.63%, NSYS -2.10%, while IRIX +4.98%. Momentum scanner only flagged IINN +8.57% (no news), suggesting VVOS trading was more stock-specific than part of a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 19 | Q3 2025 results | Neutral | -4.5% | Reported strong Q3 revenue growth driven by SCN acquisition amid operating loss. |
| Nov 19 | Earnings scheduling | Neutral | -4.5% | Announced timing of Q3 2025 financial results release and conference call. |
| Sep 30 | Clinical data update | Positive | -1.0% | Released additional pediatric ADHD and OSA data showing strong improvements with DNA device. |
| Sep 17 | Clinical trial results | Positive | +3.5% | Announced landmark pediatric OSA trial with high response and airway volume gains. |
| Aug 19 | Q2 2025 results | Negative | -3.3% | Reported Q2 revenue decline year over year and higher operating expenses despite SCN acquisition. |
Recent financial and operational updates (Q2/Q3 results and guidance) have tended to coincide with modest negative price reactions, while major clinical data has produced mixed responses despite positive trial outcomes.
Over the last six months, Vivos reported a strategic pivot with the SCN acquisition and evolving sleep-center model, reflected in Q2 and Q3 2025 updates showing higher revenue but continued operating losses. Two pediatric OSA clinical releases in September 2025 highlighted strong efficacy for the DNA device, yet price reactions were modest or negative. Against this backdrop, the new fireside chat announcement on Dec 16, 2025 centers on discussing strategy, execution, market opportunity, and financial plans rather than disclosing new metrics.
Regulatory & Risk Context
An amended S-3/A shelf registration dated Sep 5, 2025 is active, with at least one usage indicated by a 424B5 prospectus supplement on Oct 24, 2025. The shelf is recorded as not yet effective in this context, but its presence and prior ATM-related activity highlight an established framework for potential future equity issuance.
Market Pulse Summary
This announcement highlights an upcoming fireside chat on December 16, 2025 where Vivos management plans to discuss its strategic business model pivot, operational execution, market opportunity, and financial strategies. In recent quarters, filings and earnings releases have shown higher revenue but continued losses and going‑concern language, while clinical updates underscored promising pediatric OSA data. Investors may focus on how management frames growth, financing plans, and execution risk during this event.
Key Terms
obstructive sleep apnea medical
AI-generated analysis. Not financial advice.
LITTLETON, Colo., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS), a leading medical device and healthcare services company specializing in the delivery of highly effective diagnostic procedures and proprietary treatments for sleep related breathing disorders, including obstructive sleep apnea (OSA), today announced that the Company’s CEO Kirk Huntsman and CFO Brad Amman will participate in a fireside chat with Robert Sassoon, senior research analyst of Water Tower Research (“WTR”) on Tuesday, December 16, 2025, at 11:00 am ET.
Vivos management will discuss the strategic business model pivot and operational execution; the market opportunity and competitive environment; and Vivos’ growth and financial strategies.
To register for this listen-only event, please visit:
The replay of the fireside chat will be available for 30 days in the “Investor Relations” section on Vivos’ website at www.vivos.com.
About Vivos Therapeutics, Inc.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults. Vivos’ devices have been cleared by the U.S. Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA and moderate-to-severe OSA in children ages 6 to 17. Vivos’ groundbreaking Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k) cleared technology for treating severe OSA in adults and the first to receive clearance for treating moderate to severe OSA in children.
OSA affects over 1 billion people worldwide, yet
Founded in 2016 and based in Littleton, Colorado, Vivos is working to change this. Through innovative technology, education, and acquisitions of, or commercial collaborations with, sleep healthcare providers, Vivos is empowering healthcare providers to address the complex needs of OSA patients more thoroughly.
Vivos calls the use of its appliances and protocols to treat OSA The Vivos Method, which offers a proprietary, clinically effective solution that is nonsurgical, noninvasive, and nonpharmaceutical, providing hope to allow patients to Breathe New Life.
For more information, visit www.vivos.com.
Cautionary Note Regarding Forward-Looking Statements
This press release, the online presentation described herein, including statements of the Company’s management and other parties made in connection therewith, contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events. Words such as “may”, “would”, “should”, “expects”, “projects,” “potential,” “intends”, “plans”, “believes”, “anticipates”, “hopes”, “estimates”, “goal”. “aim” and variations of such words and similar expressions are intended to identify forward-looking statements. In this press release, forward-looking statements include, without limitation, those relating to (i) the actual future impact of Vivos’ strategic acquisition and alliance model on its future revenues and results of operations and (ii) the anticipated benefits and potential expansion of Vivos’ marketing and distribution model as described herein. These statements involve significant known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos’ control. Actual results may differ materially and adversely from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to: (i) the risk that Vivos may be unable to continue to integrate business from the acquisition and alliance model into its own or otherwise implement sales, marketing and other strategies that increase revenues, (ii) the risk that some patients may not achieve the desired results from using Vivos’ products, (iii) risks associated with regulatory scrutiny of and adverse publicity in the sleep apnea diagnosis and treatment sector; (iv) the risk that Vivos may be unable to secure additional financing to acquire additional sleep centers practices on reasonable terms when needed, if at all, or maintain its Nasdaq listing, (v) market and other conditions that could impact Vivos’ business or ability to obtain financing, and (vi) other risk factors described in Vivos’ filings with the Securities and Exchange Commission (“SEC”). Vivos’ filings can be obtained free of charge on the SEC’s website at www.sec.gov. Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos’ expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based.
Media Inquiries:
Jennifer Hauser, Executive Assistant to the CEO
Investor Relations Contact
investors@vivoslife.com
FAQ
When will Vivos Therapeutics (VVOS) hold the Water Tower Research fireside chat?
Who from Vivos (VVOS) will participate in the December 16, 2025 fireside chat?
What topics will Vivos (VVOS) cover in the December 16, 2025 fireside chat?
How can investors register for the Vivos (VVOS) fireside chat on December 16, 2025?
Will there be a replay of the Vivos (VVOS) fireside chat and for how long?
